FDA Rejects Sunovion's COPD Therapy

May 30, 2017

The U.S. FDA has issued a Complete Response Letter for Sunovion Pharmaceutical's New Drug Application for a therapy aiming to treat chronic obstructive pulmonary disease.

Sunovion, the U..S subsidiary of Japan's Sumitomo Dainippon, was hoping its SUN-101/eFlow therapy would become the first nebulized long-acting muscarinic antagonist for COPD.

In a brief presss release, the MA-based biotech said that regulators were not asking for new trials and that Sunovion would work with the FDA to determine a path forward.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments